Scriptaid, a Novel Histone Deacetylase Inhibitor, Protects Against Traumatic Brain Injury via Modulation of PTEN and AKT Pathway: Scriptaid Protects Against TBI via AKT

Neurotherapeutics

Volumn 10, Issue 1, 2013, Pages 124-142

  Wang, Guohua ^a,b,d   Jiang, Xiaoyan ^a   Pu, Hongjian ^a   Zhang, Wenting ^a   An, Chengrui ^a   Hu, Xiaoming ^b,e   Liou, Anthony Kian Fong ^b,e   Leak, Rehana K ^c   Gao, Yanqin ^a,b,f   Chen, Jun ^a,b,e,f  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c DUQUESNE UNIVERSITY   (United States)

^d NANTONG UNIVERSITY   (China)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

CCI; Histone deacetylase inhibitor; Long term protection; p AKT; PTEN; TBI

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL SURVIVAL; CHROMOSOME 10; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; HIPPOCAMPAL CA3 REGION; MALE; MOTOR ACTIVITY; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; TRAUMATIC BRAIN INJURY; TREATMENT RESPONSE;

EID: 84873194154     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0157-2     Document Type: Article

References (66)

1. Park HK, Fernandez II, Dujovny M, Diaz FG. Experimental animal models of traumatic brain injury: medical and biomechanical mechanism. Crit Rev Neurosurg 1999; 9: 44-52.
2. Stoica BA, Faden AI. Cell death mechanisms and modulation in traumatic brain injury. Neurotherapeutics 2010; 7: 3-12.
3. Maas AIR, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol 2008; 7: 728-741.
4. Wang GH, Zhang XG, Jiang ZL, et al. Neuroprotective effects of hyperbaric oxygen treatment on traumatic brain injury in the rat. J Neurotrauma 2010; 27: 1733-1743.
5. Sande A, West C. Traumatic brain injury: a review of pathophysiology and management. J Vet Emerg Crit Care (San Antonio) 2010; 20: 177-190.
6. Shlosberg D, Benifla M, Kaufer D, Friedman A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nature reviews 2010; 6: 393-403.
7. Greve MW, Zink BJ. Pathophysiology of traumatic brain injury. Mount Sinai J Med 2009; 76: 97-104.
8. Adamides AA, Winter CD, Lewis PM, Cooper DJ, Kossmann T, Rosenfeld JV. Current controversies in the management of patients with severe traumatic brain injury. ANZ J Surg 2006; 76: 163-174.
9. Schneider G, Fries P, Wagner-Jochem D, et al. Pathophysiological changes after traumatic brain injury: comparison of two experimental animal models by means of MRI. Magma 2002; 14: 233-241.
10. Stoica B, Byrnes K, Faden AI. Multifunctional drug treatment in neurotrauma. Neurotherapeutics 2009; 6: 14-27.
11. Shein NA, Shohami E. Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries. Mol Med 2011; 17: 448-456.
12. Dash PK, Orsi SA, Moore AN. Histone deactylase inhibition combined with behavioral therapy enhances learning and memory following traumatic brain injury. Neuroscience 2009; 163: 1-8.
13. Shein NA, Grigoriadis N, Alexandrovich AG, et al. Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. Faseb J 2009; 23: 4266-4275.
14. Crosson CE, Mani SK, Husain S, Alsarraf O, Menick DR. Inhibition of histone deacetylase protects the retina from ischemic injury. Invest Ophthalmol Vis Sci 2010; 51: 3639-3645.
15. Hu X, Xu C, Zhou X, et al. Sodium butyrate protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Biomed Pharmacother 2010.
16. Zhang LX, Zhao Y, Cheng G et al. Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition. Am J Physiol 2010; 298: H2154-H2163.
17. Zhang Z, Qin X, Tong N, et al. Valproic acid-mediated neuroprotection in retinal ischemia injury via histone deacetylase inhibition and transcriptional activation. Expe Eye Res 2012; 94: 98-108.
18. Gray SG, Dangond F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 2006; 1: 67-75.
19. Zhang F, Shi Y, Wang L, Sriram S. Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis. PloS One 2011; 6: e16795.
20. Govindarajan N, Agis-Balboa RC, Walter J, Sananbenesi F, Fischer A. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J Alzheimers Dis 2011; 26: 187-197.
21. Kilgore M, Miller CA, Fass DM, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010; 35: 870-880.
22. Venkataramani V, Rossner C, Iffland L, et al. Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J Biol Chem 2010; 285: 10678-10689.
23. Thomas EA, Coppola G, Desplats PA, et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci U S A 2008; 105: 15564-15569.
24. Zadori D, Geisz A, Vamos E, Vecsei L, Klivenyi P. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacol Biochem Behav 2009; 94: 148-153.
25. Lyssiotis CA, Walker J, Wu C, Kondo T, Schultz PG, Wu X. Inhibition of histone deacetylase activity induces developmental plasticity in oligodendrocyte precursor cells. Proc Natl Acad Sci U S A 2007; 104: 14982-14987.
26. Miller CA, Campbell SL, Sweatt JD. DNA methylation and histone acetylation work in concert to regulate memory formation and synaptic plasticity. Neurobiol Learn Mem 2008; 89: 599-603.
27. Monsey MS, Ota KT, Akingbade IF, Hong ES, Schafe GE. Epigenetic alterations are critical for fear memory consolidation and synaptic plasticity in the lateral amygdala. PloS One 2011; 6: e19958.
28. Morita K, Gotohda T, Arimochi H, Lee MS, Her S. Histone deacetylase inhibitors promote neurosteroid-mediated cell differentiation and enhance serotonin-stimulated brain-derived neurotrophic factor gene expression in rat C6 glioma cells. J Neurosci Res 2009; 87: 2608-2614.
29. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008; 7: 854-868.
30. Langley B, Gensert JM, Beal MF, Ratan RR. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets 2005; 4: 41-50.
31. Dash PK, Orsi SA, Zhang M, et al. Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PloS One 2010; 5: e11383.
32. Zhang B, West EJ, van KC, et al. HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res 2008; 1226: 181-191.
33. Chua KS, Ng YS, Yap SG, Bok CW. A brief review of traumatic brain injury rehabilitation. Ann Acad Med Singapore 2007; 36: 31-42.
34. Gao WM, Chadha MS, Kline AE, et al, Immunohistochemical analysis of histone H3 acetylation and methylation - evidence for altered epigenetic signaling following traumatic brain injury in immature rats. Brain Res 2006; 1070: 31-34.
35. Takai N, Ueda T, Nishida M, Nasu K, Narahara H. A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells. Int J Mol Med 2006; 17: 323-329.
36. Li X, Blizzard KK, Zeng Z, DeVries AC, Hurn PD, McCullough LD. Chronic behavioral testing after focal ischemia in the mouse: functional recovery and the effects of gender. Exp Neurol 2004; 187: 94-104.
37. Brody DL, Holtzman DM. Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury. Exp Neurol 2006; 197: 330-340.
38. Stetler RA, Gao Y, Zukin RS, et al. Apurinic/apyrimidinic endonuclease APE1 is required for PACAP-induced neuroprotection against global cerebral ischemia. Proc Natl Acad Sci U S A 2010; 107: 3204-3209.
39. Cao G, Xing J, Xiao X, et al. Critical role of calpain I in mitochondrial release of apoptosis-inducing factor in ischemic neuronal injury. J Neurosci 2007; 27: 9278-9293.
40. Bian M, Liu J, Hong X, et al. Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in mice. PloS One 2012; 7: e39953.
41. Furutani R, Kibayashi K. Morphological alteration and reduction of MAP2-immunoreactivity in pyramidal neurons of cerebral cortex in a rat model of focal cortical compression. J Neurotrauma 2012; 29: 1266-1276.
42. Rink A, Fung KM, Trojanowski JQ, Lee VM, Neugebauer E, McIntosh TK. Evidence of apoptotic cell death after experimental traumatic brain injury in the rat. Am J Pathol 1995; 147: 1575-1583.
43. Dash PK, Mach SA, Moore AN. Enhanced neurogenesis in the rodent hippocampus following traumatic brain injury. J Neurosci Res 2001; 63: 313-319.
44. Wang GH, Jiang ZL, Li YC, et al. Free-radical scavenger edaravone treatment confers neuroprotection against traumatic brain injury in rats. J Neurotrauma 2011; 28: 2123-2134.
45. Fujii D, Ahmed I. Psychotic disorder following traumatic brain injury: a conceptual framework. Cogn Neuropsychiatry 2002; 7: 41-62.
46. Reeves RR, Panguluri RL. Neuropsychiatric complications of traumatic brain injury. J Psychosoc Nurs Ment Health Serv 2011; 49: 42-50.
47. Hesdorffer DC, Rauch SL, Tamminga CA. Long-term psychiatric outcomes following traumatic brain injury: a review of the literature. J Head Trauma Rehabil 2009; 24: 452-459.
48. De FP, Fellus J, Polito MZ, Thompson JW, Moser RS, DeLuca J. The new neuroscience frontier: promoting neuroplasticity and brain repair in traumatic brain injury. Clin Neuropsychol 2009; 23: 1391-1399.
49. Stoica BA, Faden AI. Cell death mechanisms and modulation in traumatic brain injury. Neurotherapeutics 2010; 7: 3-12.
50. Sanchez C, Diaz-Nido J, Avila J. Phosphorylation of microtubule-associated protein 2 (MAP2) and its relevance for the regulation of the neuronal cytoskeleton function. Prog Neurobiol 2000; 61: 133-168.
51. Schmued LC, Stowers CC, Scallet AC, Xu L. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res 2005; 1035: 24-31.
52. Schmued LC, Hopkins KJ. Fluoro-Jade B. A high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 2000; 874: 123-130.
53. Fischer A, Sananbenesi F, Mungenast A, Tsai LH. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 2010; 31: 605-617.
54. Gottesfeld JM, Pandolfo M. Development of histone deacetylase inhibitors as therapeutics for neurological disease. Future Neurol 2009; 4: 775-784.
55. Saha RN, Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ 2006; 13: 539-550.
56. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007; 26: 5310-5318.
57. Dietz KC, Casaccia P. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol Res 2010; 62: 11-17.
58. Jin K, Mao XO, Simon RP, Greenberg DA. Cyclic AMP response element binding protein (CREB) and CREB binding protein (CBP) in global cerebral ischemia. J Mol Neurosci 2001; 16: 49-56.
59. Rouaux C, Jokic N, Mbebi C, Boutillier S, Loeffler JP, Boutillier AL. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J 2003; 22: 6537-6549.
60. Shein NA, Shohami E. Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries. Mol Med 2011.
61. Georgescu MM. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 2010; 1: 1170-1177.
62. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev 2012; 13: 283-296.
63. Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem 2005; 280: 35195-35202.
64. Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 2001; 276: 48627-48630.
65. Tamguney T, Stokoe D. New insights into PTEN. J Cell Sci 2007; 120: 4071-4079.
66. Azevedo FA, Carvalho LR, Grinberg LT, et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J Comp Neurol 2009; 513: 532-541.